vs
Claritev Corp（CTEV）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Claritev Corp的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$246.6M vs $207.3M），Claritev Corp净利率更高（-32.7% vs -62.0%，领先29.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 6.2%），Claritev Corp自由现金流更多（$36.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 2.5%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CTEV vs RARE — 直观对比
营收规模更大
CTEV
是对方的1.2倍
$207.3M
营收增速更快
RARE
高出19.7%
6.2%
净利率更高
CTEV
高出29.3%
-62.0%
自由现金流更多
CTEV
多$137.1M
$-100.8M
两年增速更快
RARE
近两年复合增速
2.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $246.6M | $207.3M |
| 净利润 | $-80.6M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | -3.1% | -54.7% |
| 净利率 | -32.7% | -62.0% |
| 营收同比 | 6.2% | 25.9% |
| 净利润同比 | 41.6% | 3.5% |
| 每股收益（稀释后） | $-4.88 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTEVRARE
| Q4 25 | $246.6M | $207.3M | ||
| Q3 25 | $246.0M | $159.9M | ||
| Q2 25 | $241.6M | $166.5M | ||
| Q1 25 | $231.3M | $139.3M | ||
| Q4 24 | $232.1M | $164.6M | ||
| Q3 24 | $230.5M | $139.5M | ||
| Q2 24 | $233.5M | $147.0M | ||
| Q1 24 | $234.5M | $108.8M |
净利润CTEVRARE
| Q4 25 | $-80.6M | $-128.6M | ||
| Q3 25 | $-69.8M | $-180.4M | ||
| Q2 25 | $-62.6M | $-115.0M | ||
| Q1 25 | $-71.3M | $-151.1M | ||
| Q4 24 | $-138.0M | $-133.2M | ||
| Q3 24 | $-391.4M | $-133.5M | ||
| Q2 24 | $-576.7M | $-131.6M | ||
| Q1 24 | $-539.7M | $-170.7M |
营业利润率CTEVRARE
| Q4 25 | -3.1% | -54.7% | ||
| Q3 25 | 4.1% | -106.9% | ||
| Q2 25 | 6.9% | -64.8% | ||
| Q1 25 | 4.2% | -102.6% | ||
| Q4 24 | -17.8% | -74.3% | ||
| Q3 24 | -146.7% | -94.6% | ||
| Q2 24 | -224.4% | -79.1% | ||
| Q1 24 | -207.4% | -151.9% |
净利率CTEVRARE
| Q4 25 | -32.7% | -62.0% | ||
| Q3 25 | -28.4% | -112.8% | ||
| Q2 25 | -25.9% | -69.0% | ||
| Q1 25 | -30.8% | -108.5% | ||
| Q4 24 | -59.4% | -80.9% | ||
| Q3 24 | -169.8% | -95.7% | ||
| Q2 24 | -247.0% | -89.5% | ||
| Q1 24 | -230.1% | -156.8% |
每股收益（稀释后）CTEVRARE
| Q4 25 | $-4.88 | $-1.28 | ||
| Q3 25 | $-4.23 | $-1.81 | ||
| Q2 25 | $-3.81 | $-1.17 | ||
| Q1 25 | $-4.38 | $-1.57 | ||
| Q4 24 | $-8.49 | $-1.34 | ||
| Q3 24 | $-24.25 | $-1.40 | ||
| Q2 24 | $-35.78 | $-1.52 | ||
| Q1 24 | $-33.40 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $16.8M | $421.0M |
| 总债务越低越好 | $4.6B | — |
| 股东权益账面价值 | $-173.9M | $-80.0M |
| 总资产 | $4.9B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTEVRARE
| Q4 25 | $16.8M | $421.0M | ||
| Q3 25 | $39.2M | $202.5M | ||
| Q2 25 | $56.4M | $176.3M | ||
| Q1 25 | $23.1M | $127.1M | ||
| Q4 24 | $16.8M | $174.0M | ||
| Q3 24 | $86.6M | $150.6M | ||
| Q2 24 | $48.8M | $480.7M | ||
| Q1 24 | $58.7M | $112.3M |
总债务CTEVRARE
| Q4 25 | $4.6B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $4.5B | — | ||
| Q1 24 | $4.5B | — |
股东权益CTEVRARE
| Q4 25 | $-173.9M | $-80.0M | ||
| Q3 25 | $-101.8M | $9.2M | ||
| Q2 25 | $-39.9M | $151.3M | ||
| Q1 25 | $14.8M | $144.2M | ||
| Q4 24 | $84.0M | $255.0M | ||
| Q3 24 | $207.6M | $346.8M | ||
| Q2 24 | $603.4M | $432.4M | ||
| Q1 24 | $1.2B | $140.3M |
总资产CTEVRARE
| Q4 25 | $4.9B | $1.5B | ||
| Q3 25 | $5.0B | $1.2B | ||
| Q2 25 | $5.1B | $1.3B | ||
| Q1 25 | $5.1B | $1.3B | ||
| Q4 24 | $5.2B | $1.5B | ||
| Q3 24 | $5.3B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B | ||
| Q1 24 | $6.4B | $1.3B |
负债/权益比CTEVRARE
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 304.87× | — | ||
| Q4 24 | 53.67× | — | ||
| Q3 24 | 21.73× | — | ||
| Q2 24 | 7.48× | — | ||
| Q1 24 | 3.85× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $66.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $36.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 14.8% | -48.6% |
| 资本支出强度资本支出/营收 | 12.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CTEVRARE
| Q4 25 | $66.3M | $-99.8M | ||
| Q3 25 | $19.9M | $-91.4M | ||
| Q2 25 | $61.2M | $-108.3M | ||
| Q1 25 | $-30.1M | $-166.5M | ||
| Q4 24 | $-33.4M | $-79.3M | ||
| Q3 24 | $72.8M | $-67.0M | ||
| Q2 24 | $18.5M | $-77.0M | ||
| Q1 24 | $49.7M | $-190.7M |
自由现金流CTEVRARE
| Q4 25 | $36.4M | $-100.8M | ||
| Q3 25 | $-16.3M | $-92.7M | ||
| Q2 25 | $36.6M | $-110.7M | ||
| Q1 25 | $-68.9M | $-167.8M | ||
| Q4 24 | $-63.8M | $-79.5M | ||
| Q3 24 | $41.1M | $-68.6M | ||
| Q2 24 | $-7.0M | $-79.0M | ||
| Q1 24 | $19.2M | $-193.9M |
自由现金流率CTEVRARE
| Q4 25 | 14.8% | -48.6% | ||
| Q3 25 | -6.6% | -58.0% | ||
| Q2 25 | 15.2% | -66.5% | ||
| Q1 25 | -29.8% | -120.5% | ||
| Q4 24 | -27.5% | -48.3% | ||
| Q3 24 | 17.8% | -49.2% | ||
| Q2 24 | -3.0% | -53.7% | ||
| Q1 24 | 8.2% | -178.2% |
资本支出强度CTEVRARE
| Q4 25 | 12.1% | 0.5% | ||
| Q3 25 | 14.7% | 0.8% | ||
| Q2 25 | 10.2% | 1.5% | ||
| Q1 25 | 16.8% | 1.0% | ||
| Q4 24 | 13.1% | 0.1% | ||
| Q3 24 | 13.8% | 1.2% | ||
| Q2 24 | 10.9% | 1.4% | ||
| Q1 24 | 13.0% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTEV
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
